New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT05223231

Completed Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new drug called LBL-019, given alone or with another immunotherapy, in 26 adults with advanced cancers that no longer responded to standard treatments. The main goal was to check safety and find the right dose. Researchers also looked at whether the drug helped shrink tumors or control the disease. Since participants had late-stage cancers and the study was small, this is not a cure but aims to manage the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT TUMORS

Contacts and locations

Locations

Fujian Cancer Hospital

Fuzhou, Fujian, 350000, China
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital

Changsha, Hunan, 410006, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China
The first affiliated hospital with Nanjing medical university

Nanjing, Jiangsu, 210000, China
Union hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.